Talazoparib Tosylate
Talazoparib tosylate is the toluenesulfonate salt form of talazoparib, a potent PARP1/2 inhibitor and PARP-trapping agent used for BRCA-mutated locally advanced or metastatic breast cancer, and investigated in colorectal and other BRCA-associated cancers. See talazoparib for complete pharmacological details.
Berat Molekul
552,6000 g/mol
TPSA
147,00 Ų
Area Terapeutik
Mekanisme Kerja
Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.
Struktur 2D
Cite this structure
Embed this structure
SMILES
Cc1ccc(S(=O)(=O)O)cc1.Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1
InChI
InChI=1S/C19H14F2N6O.C7H8O3S/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28;1-6-2-4-7(5-3-6)11(8,9)10/h2-8,15-16,24H,1H3,(H,26,28);2-5H,1H3,(H,8,9,10)/t15-,16-;/m1./s1
Molecular Formula
C26H22F2N6O4S
HBD / HBA
3 / 10
Ikatan yang Dapat Dirotasi
3
Atom Berat
39
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
Talazoparib tosylate is the toluenesulfonate salt form of talazoparib, a potent PARP1/2 inhibitor and PARP-trapping agent used for BRCA-mutated locally advanced or metastatic breast cancer, and investigated in colorectal and other BRCA-associated cancers. See talazoparib for complete pharmacological details.
Inhibits poly(ADP-ribose) polymerase (PARP) enzymes involved in DNA single-strand break repair, exploiting homologous recombination deficiency in cancer cells to cause synthetic lethality.
Yes, Talazoparib Tosylate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3137318. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 135565654. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="talazoparib-tosylate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/talazoparib-tosylate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/talazoparib-tosylate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/talazoparib-tosylate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="talazoparib-tosylate"></drugfyi-drug>